21-04-06
Serologicals Corporation (NASDAQ: SERO) and the Australian Stem Cell Centre (ASCC) announced today that that they have signed an agreement whereby Chemicon International, Inc., Serologicals’ wholly-owned subsidiary, has obtained exclusive rights to commercialise, market and distribute stem cell reagents developed at the ASCC to scientists all over the world.
Initial products which will be available to researchers through Chemicon include a novel and proprietary stem cell isolation kit, various proteins and antibodies.
The ASCC is assisting Chemicon in new product development in the research reagent area and expects that other life science tools will also become part of this exclusive research collaboration as they become ready to market.
Download the full media release below.
Downloads
Chemicon ASCC Agreement (25398)
Other Reports